Online citations, reference lists, and bibliographies.
← Back to Search

Pharmaceutical Aspects Of Intranasal Delivery Of Vaccines Using Particulate Systems.

S. Sharma, T. Mukkur, H. Benson, Y. Chen
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The nasal route offers a promising opportunity for the delivery of vaccines. This review analyses the opportunities and novel delivery strategies based on particulate systems for the nasal delivery of vaccines, including liposomes, proteosomes, virosomes, nano- and microparticulate systems, with and without adjuvants. The influence of pharmaceutical aspects of the particulate formulations on nasal delivery is analysed. Recently developed delivery devices for nasal vaccination are also described. Potential barriers to clinical and commercial success of some novel intranasal vaccines are critically evaluated. Although particulate systems may offer potential in the nasal delivery of vaccines by enhancing uptake by antigen-presenting cells, the real success in enhancement of vaccine delivery can only be achieved by careful design and manipulation of physicochemical properties of particulate vaccine delivery systems.
This paper references
10.4049/jimmunol.170.2.816
Microbial Colonization Drives Lymphocyte Accumulation and Differentiation in the Follicle-Associated Epithelium of Peyer’s Patches1
T. Yamanaka (2003)
10.4049/jimmunol.173.5.2985
Phosphatidylserine Regulates the Maturation of Human Dendritic Cells1
X. Chen (2004)
10.1016/S0142-9612(97)00227-5
Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions.
A. K. Andrianov (1998)
10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S
The antigen dose determines T helper subset development by regulation of CD40 ligand
C. Ruedl (2000)
10.1016/S0142-9612(98)00042-8
Semisynthetic resorbable materials from hyaluronan esterification.
D. Campoccia (1998)
10.1016/J.JCONREL.2005.11.014
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
M. Amidi (2006)
10.1016/J.IJPHARM.2004.09.002
PLA-PEG particles as nasal protein carriers: the influence of the particle size.
A. Vila (2005)
10.1016/S0264-410X(98)00440-X
Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs).
R. Glueck (1999)
HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
T. Vancott (1998)
10.1093/INTIMM/10.5.651
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
M. Ryan (1998)
10.1016/J.VACCINE.2006.02.032
Local immune responses following nasal delivery of an adjuvanted influenza vaccine.
J. Scheerlinck (2006)
10.1007/s11095-007-9310-8
Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes
R. Voltan (2007)
10.1016/J.EJPS.2005.04.015
Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium.
A. des Rieux (2005)
10.1128/IAI.68.10.5509-5516.2000
Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen
N. Childers (2000)
10.1084/JEM.180.1.15
Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches
B. D. Jones (1994)
Identification of some of the physico-chemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery
H. O. Alpar (1994)
10.1016/S0264-410X(01)00193-1
Towards the rational design of Th1 adjuvants.
P. Moingeon (2001)
10.1089/JAM.2004.17.249
Bi-directional nasal delivery of aerosols can prevent lung deposition.
P. Djupesland (2004)
10.1016/S0167-5699(98)01307-3
Immunology of the tonsils.
M. Perry (1998)
10.1016/S0264-410X(02)00266-9
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.
A. Jegerlehner (2002)
10.1016/J.VACCINE.2005.01.138
Strategy for determination of an efficient Cochleate particle size.
D. Gil (2006)
10.1615/CRITREVIMMUNOL.V21.I1-3.70
The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
M. McCluskie (2001)
10.1089/089426802320282347
Intranasal immunization against influenza.
R. Glueck (2002)
10.1038/nri1777
Mucosal vaccines: the promise and the challenge
M. Neutra (2006)
10.1016/J.VACCINE.2005.07.088
Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
J. Treanor (2006)
10.1089/AID.2004.20.1269
Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.
M. Vajdy (2004)
10.1016/J.JCONREL.2006.06.029
Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo.
Mohamed M. Issa (2006)
10.1016/S0031-6865(97)00021-6
Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations.
V. Baeyens (1997)
10.4161/hv.1.1.1553
A Phase I, Randomized, Controlled Trial to Study the Reactogenicity and Immunogenicity of a Nasal, Inactivated Trivalent Influenza Virus Vaccine in Healthy Adults
S. Halperin (2005)
10.1016/S0264-410X(97)00047-9
Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres.
Y. Men (1997)
10.1016/S0264-410X(02)00435-8
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.
I. Gutierro (2002)
10.2174/156720106778559029
Particulate systems as adjuvants and carriers for peptide and protein antigens.
M. Liang (2006)
10.1016/S0264-410X(00)00553-3
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
M. Pizza (2001)
10.1016/J.TUBE.2007.05.005
Progress towards an AIDS mucosal vaccine: an overview.
Y. Yuki (2007)
10.1128/JVI.80.10.4962-4970.2006
Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers
I. Stephenson (2006)
10.1016/S0959-8049(01)00084-3
A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration.
S. El mir (2001)
10.1016/J.VACCINE.2006.01.011
Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
K. S. Jaganathan (2006)
10.1016/j.vaccine.2008.02.058
Surface modified liposomes for nasal delivery of DNA vaccine.
K. Khatri (2008)
10.1038/nri1439
NALT- versus PEYER'S-patch-mediated mucosal immunity
H. Kiyono (2004)
10.1126/SCIENCE.8248784
The influence of antigen organization on B cell responsiveness.
M. Bachmann (1993)
10.1211/jpp.58.6.0002
Particulate delivery systems for vaccines: what can we expect?
Vincent W. Bramwell (2006)
Permeation enhancers in the transmucosal delivery of macromolecules.
S. Sharma (2006)
10.1016/S0264-410X(01)00292-4
Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization.
R. Glueck (2001)
10.1007/978-3-642-74529-4_2
Overview of the mucosal immune system.
P. Brandtzaeg (1989)
10.1023/A:1016104910582
Recent Advances in Vaccine Adjuvants
M. Singh (2004)
10.1038/sj.gt.3301212
Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis
S C Hyde (2000)
10.1128/IAI.65.8.3239-3247.1997
Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages.
C. Salkowski (1997)
10.1111/j.1365-3083.2006.01730.x
Oral Spray Immunization May Be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies but not Nasal Mucosal or Cellular Immunity
H. Bakke (2006)
10.1016/j.biomaterials.2007.12.025
The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization.
H. Jiang (2008)
10.1016/J.VACCINE.2005.12.017
A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
A. Joseph (2006)
10.1023/A:1011929016601
Chitosan and its use as a pharmaceutical excipient.
L. Illum (1998)
10.1007/s00795-006-0335-6
Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue
Y. Fujimura (2006)
The number and distribution of lymphoid follicles in the human large intestine.
J. Langman (1986)
10.1016/0264-410X(89)90055-8
Intranasal immunization with proteoliposomes protects against influenza.
N. el Guink (1989)
10.1016/J.BBAMEM.2004.02.007
Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin.
K. Romøren (2004)
10.1016/J.YMETH.2006.05.016
Pathogen recognition and development of particulate vaccines: does size matter?
S. Xiang (2006)
10.1080/10611860701637966
Rational design of nasal vaccines
B. Slütter (2008)
10.1586/erv.10.174
CpG DNA as a vaccine adjuvant
C. Bode (2011)
10.1016/J.VACCINE.2004.03.033
Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
W. Xu (2004)
10.1128/IAI.37.1.271-280.1982
Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens.
C. Frasch (1982)
10.1196/annals.1384.012
Do Salivary Antibodies Reliably Reflect Both Mucosal and Systemic Immunity?
P. Brandtzaeg (2007)
10.1146/ANNUREV.IMMUNOL.14.1.275
Antigen sampling across epithelial barriers and induction of mucosal immune responses.
M. Neutra (1996)
10.1097/01.MLG.0000199741.08517.99
Breath Actuated Device Improves Delivery to Target Sites Beyond the Nasal Valve
P. Djupesland (2006)
10.1016/S0169-409X(01)00197-1
Chitosan for mucosal vaccination.
I. M. van der Lubben (2001)
10.1016/S1359-6446(05)03600-7
The rational design of vaccines
Vincent W. Bramwell (2005)
10.1586/14760584.6.5.797
Nanoparticles and microparticles as vaccine-delivery systems
M. Singh (2007)
10.1016/S0171-2985(11)80239-1
Mechanism of liposome adjuvanticity: an in vivo approach.
A. Fortin (1993)
10.1016/0264-410X(93)90013-N
Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic E. coli.
R. Reid (1993)
10.1016/0264-410X(94)00083-Y
Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes.
R. Levi (1995)
10.1083/JCB.151.3.673
The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments
K. Mahnke (2000)
10.1016/S0264-410X(98)00089-9
Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines.
J. Eyles (1998)
10.1016/S0264-410X(01)00268-7
Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.
M. Plante (2001)
10.1016/S0169-409X(01)00173-9
Polymeric lamellar substrate particles for intranasal vaccination.
I. Jabbal‐Gill (2001)
10.1016/J.VACCINE.2003.10.020
Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.
A. M. Carcaboso (2004)
10.1016/0264-410X(92)90021-B
The mucosal immune system: from fundamental concepts to vaccine development.
J. Mcghee (1992)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/J.JCONREL.2004.04.026
Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.
A. Vila (2004)
10.1038/71916
Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide)
Gaozhong Zhu (2000)
Induction of immunity against hepatitis B virus surface antigen by intranasal DNA vaccination using a cationic emulsion as a mucosal gene carrier.
T. Kim (2006)
10.1021/BC00028A010
Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials.
T. Pouyani (1994)
10.1016/S0168-3659(98)00097-2
Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery.
F. Maclaughlin (1998)
10.1046/j.1365-2567.1998.00420.x
Intranasal immunization with polymer‐grafted microparticles activates the nasal‐associated lymphoid tissue and draining lymph nodes
Heritage (1998)
10.1016/S0264-410X(97)00249-1
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
J. Eyles (1998)
10.1016/J.VACCINE.2006.12.001
Induction of secretory immunity and memory at mucosal surfaces.
P. Brandtzaeg (2007)
10.1080/713840363
Physicochemical Characterization of Influenza Viral Vaccine Loaded Surfactant Vesicles
S. Chattaraj (2003)
10.1016/J.TUBE.2006.12.006
Should a new tuberculosis vaccine be administered intranasally?
G. Källenius (2007)
10.1586/14760584.4.2.185
Nanoparticles as carriers for nasal vaccine delivery
M. Köping-Höggård (2005)
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
10.1002/JPS.20718
Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?
L. Illum (2007)
10.1016/0378-5173(94)00226-U
Novel vaginal delivery systems for calcitonin: I. Evaluation of HYAFF/calcitonin microspheres in rats
J. Richardson (1995)
10.1016/J.VACCINE.2007.05.052
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
L. Buonaguro (2007)
10.1016/S0169-409X(98)00014-3
Targeting immune response induction with cochleate and liposome-based vaccines.
Mannino (1998)
10.1021/BC049956F
Acid-degradable particles for protein-based vaccines: enhanced survival rate for tumor-challenged mice using ovalbumin model.
Stephany M. Standley (2004)
10.1056/NEJMP048006
Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy.
R. Couch (2004)
10.1023/B:PHAM.0000022414.17183.58
Novel Chitosan Particles and Chitosan-Coated Emulsions Inducing Immune Response via Intranasal Vaccine Delivery
Takahiro Nagamoto (2004)
10.1016/S0142-9612(98)00035-0
Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines.
A. Coombes (1998)
10.1016/J.IJPHARM.2006.03.047
Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
M. Tafaghodi (2006)
10.1046/j.1440-1711.1998.00743.x
Polymer‐grafted starch microparticles for oral and nasal immunization
M. Mcdermott (1998)
10.1111/j.1440-1711.2005.01315.x
Lipid based particulate formulations for the delivery of antigen
M. J. Copland (2005)
10.1089/107999099313893
Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12.
M. Baca-Estrada (1999)
10.3109/10611860108997935
Transport of Nanoparticles Across the Rat Nasal Mucosa
J. Brooking (2001)
10.1007/978-1-4615-3410-5_3
Prospects for human mucosal vaccines.
J. Mestecky (1992)
10.1016/S0264-410X(02)00545-5
Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.
A. Coulter (2003)
10.1007/978-1-4615-1823-5_15
Lipid matrix-based vaccines for mucosal and systemic immunization.
R. Mannino (1995)
10.1007/s00428-003-0898-8
The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling
Y. Fujimura (2004)
10.1016/J.TUBE.2004.09.013
Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice.
M. Haile (2005)
10.1159/000024354
The Immune Response in Adenoids and Tonsils
M. V. van Kempen (2000)
10.1093/INFDIS/163.1.1
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.
I. Onorato (1991)
10.1128/IAI.56.2.432-438.1988
Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems.
G. Kersten (1988)
10.1023/A:1012142204132
The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres
O. Johnson (2004)
10.1016/J.VACCINE.2003.08.024
Efficient delivery of DNA to dendritic cells mediated by influenza virosomes.
M. G. Cusi (2004)
10.1016/S0065-3519(99)80030-5
ISCOM: a delivery system for neonates and for mucosal administration.
B. Morein (1999)
10.1016/J.VACCINE.2003.07.022
IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques.
F. Villinger (2004)
10.1051/VETRES:2006014
Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
E. Cox (2006)
10.1016/J.VACCINE.2006.06.086
N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
M. Amidi (2007)
10.1016/J.VACCINE.2005.01.119
Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants.
J. del Campo (2006)
10.1016/S0264-410X(02)00103-2
Virosome-mediated delivery of protein antigens to dendritic cells.
L. Bungener (2002)
10.1128/IAI.67.12.6270-6280.1999
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells
E. Ryan (1999)
10.1016/S0378-5173(99)00239-2
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume.
J. Eyles (1999)
10.1211/0022357044418
Development of a single‐dose stabilized poly(d,l‐lactic‐co‐glycolic acid) microspheres‐based vaccine against hepatitis B
K. S. Jaganathan (2004)
10.1016/S0264-410X(01)00220-1
Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration.
J. Eyles (2001)
10.1056/NEJMOA030595
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.
M. Mutsch (2004)
10.3109/08982109609031122
MUCOSAL AND SYSTEMIC IMMUNIZATION USING COCHLEATE AND LIPOSOME VACCINES
S. Gould-Fogerite (1996)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I1.20
Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems.
S. Schwendeman (2002)
10.1016/j.biomaterials.2008.03.011
Enhancement of poly(orthoester) microspheres for DNA vaccine delivery by blending with poly(ethylenimine).
David N. Nguyen (2008)
10.1016/S0264-410X(03)00305-0
The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.
B. Baudner (2003)
10.1016/0264-410X(95)00011-O
Adjuvants for human vaccines--current status, problems and future prospects.
R. Gupta (1995)
10.1016/0264-410X(92)90026-G
Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine.
M. Trudel (1992)
10.1016/S0264-410X(03)00457-2
Mucosal antibody response induced with a nasal virosome-based influenza vaccine.
P. Durrer (2003)
10.1016/S0169-409X(97)00122-1
Protein release from polyphosphazene matrices.
Payne (1998)
10.1016/J.BIOMATERIALS.2007.04.023
Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives.
T. Akagi (2007)
10.1016/J.VACCINE.2003.10.054
Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
R. Lambkin (2004)
10.1016/0378-5173(94)90352-2
Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films
L. Hume (1994)
10.1016/S0167-5699(98)01413-3
Regional specialization in the mucosal immune system: what happens in the microcompartments?
P. Brandtzaeg (1999)
10.1016/S0016-5085(77)80254-0
Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: an ultrastructural study.
R. L. Owen (1977)
Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
J. Mestecky (1997)
10.1128/CMR.10.1.35
Yersinia pestis--etiologic agent of plague.
R. Perry (1997)
10.1586/14760584.2.2.285
Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines
S. Peppoloni (2003)
10.1007/s10989-004-2433-4
Chitosan-dextran Sulfate Nanoparticles for Delivery of an Anti-angiogenesis Peptide
Y. Chen (2004)
10.1016/S0264-410X(02)00513-3
New technology platforms in the development of vaccines for the future.
R. Glueck (2002)
10.1016/S0168-3659(00)00330-8
A novel bioadhesive intranasal delivery system for inactivated influenza vaccines.
M. Singh (2001)
10.4049/jimmunol.174.3.1393
Interaction between Phosphatidylserine and the Phosphatidylserine Receptor Inhibits Immune Responses In Vivo1
P. Hoffmann (2005)
10.1211/0022357001777324
Biodegradable Microparticles with Different Release Profiles: Effect on the Immune Response After a Single Administration via Intranasal and Intramuscular Routes
I. Spiers (2000)
10.1073/PNAS.97.2.811
Cationic microparticles: A potent delivery system for DNA vaccines.
M. Singh (2000)
10.1111/j.1440-1711.2004.01288.x
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines
M. Vajdy (2004)
10.4049/jimmunol.165.9.5017
Two Distinct Stages in the Transition from Naive CD4 T Cells to Effectors, Early Antigen-Dependent and Late Cytokine-Driven Expansion and Differentiation1
D. Jelley-Gibbs (2000)
10.1016/0264-410X(95)00184-3
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
A. Moore (1995)
10.1016/S0092-8674(01)00449-4
Dendritic Cells Specialized and Regulated Antigen Processing Machines
I. Mellman (2001)
10.1016/S0169-409X(01)00167-3
Microparticles for intranasal immunization.
M. Vajdy (2001)
10.1016/S0264-410X(02)00191-3
Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses.
Arnaud Debin (2002)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1016/J.ADDR.2004.09.008
Immunity in response to particulate antigen-delivery systems.
T. Storni (2005)
10.1038/NMAT1075
Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines
C. Wang (2004)
10.1038/nrd1176
Recent advances in the discovery and delivery of vaccine adjuvants
D. O'hagan (2003)
10.1016/J.VACCINE.2005.01.135
Regulatory considerations on new adjuvants and delivery systems.
D. Sesardic (2006)
10.1016/0022-1759(90)90208-D
Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms.
B. Morein (1990)
10.1016/0264-410X(94)90251-8
Activation of systemic and mucosal immune response following nasal administration of liposomes.
Y. Aramaki (1994)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1016/S0378-5173(02)00688-9
Preparation and purification of cationic solid lipid nanospheres--effects on particle size, physical stability and cell toxicity.
A. V. Heydenreich (2003)
10.1016/J.EJPB.2006.05.005
Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.
M. Tafaghodi (2006)
10.1021/BC034184T
Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
A. Roth (2004)
10.1016/S0264-410X(96)00266-6
Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.
D. I. Jones (1997)
10.1016/S0264-410X(03)00387-6
A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
T. Jones (2003)
10.1084/JEM.184.3.1045
Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting
A. Frey (1996)
10.1111/j.2042-7158.1990.tb07033.x
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
P. Jani (1990)
10.1016/0264-410X(92)90435-M
Adjuvanticity and ISCOM formation by structurally diverse saponins.
R. Bomford (1992)
10.1146/ANNUREV.CELLBIO.16.1.301
Epithelial M cells: differentiation and function.
J. Kraehenbuhl (2000)
10.1016/0005-2736(91)90388-O
On the structure of immune-stimulating saponin-lipid complexes (iscoms).
G. Kersten (1991)
10.1093/INFDIS/175.2.292
Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.
G. Lowell (1997)
10.1086/499594
A response to strategy #2: streamlining the regulatory process.
W. P. Glezen (2006)
10.1128/JVI.75.20.9713-9722.2001
Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses
R. Guerrero (2001)
10.1078/1438-4221-00288
Bordetella pertussis from functional genomics to intranasal vaccination.
C. Locht (2004)
10.1038/nm1213
Mucosal immunity and vaccines
J. Holmgren (2005)
10.4049/jimmunol.167.9.5386
Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization1
H. Staats (2001)
10.1111/j.1440-1711.2004.01293.x
Novel adjuvant based on a proteoliposome‐derived cochleate structure containing native lipopolysaccharide as a pathogen‐associated molecular pattern
O. Pérez (2004)
10.1016/S0928-0987(03)00102-7
Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles.
W. Tiyaboonchai (2003)
10.1016/S0264-410X(00)00019-0
Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses.
M. Baca-Estrada (2000)
10.1016/S0264-410X(02)00579-0
Experience with registered mucosal vaccines.
G. Dietrich (2003)
10.1006/MPAT.1993.1015
Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome-incorporated cell-surface antigens.
R. M. Brownlie (1993)
10.1016/0168-3659(94)90129-5
Hyaluronic acid ester microspheres as a nasal delivery system for insulin
L. Illum (1994)
10.1016/J.ADDR.2004.09.003
Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
Wenlei Jiang (2005)
10.1016/S0169-409X(01)00165-X
Immunostimulating complexes (ISCOMs) for nasal vaccination.
K. Hu (2001)
10.1016/S0264-410X(96)00074-6
Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres.
Y. Men (1996)
10.1016/S0169-409X(01)00171-5
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
10.1016/S0165-2427(01)00370-1
Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles.
M. Rebelatto (2001)
10.1016/S0928-0987(01)00172-5
Chitosan and its derivatives in mucosal drug and vaccine delivery.
I. M. van der Lubben (2001)
10.1016/S0952-7915(02)00384-9
Recent advances in mucosal vaccines and adjuvants.
K. Eriksson (2002)
Selective transport of IgA. Cellular and molecular aspects.
J. Mestecky (1991)
10.1016/J.IT.2004.09.005
Let's go mucosal: communication on slippery ground.
P. Brandtzaeg (2004)
10.1016/J.ADDR.2004.09.004
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery.
H. O. Alpar (2005)
10.1016/S0169-409X(01)00175-2
Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery.
P. Hoegen (2001)
10.1016/J.VACCINE.2005.12.016
Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine.
S. J. Elvin (2006)
10.1016/J.YMETH.2005.11.003
Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems
J. Singh (2006)
10.3109/10611869509015924
A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery.
T. Yoshioka (1995)
10.1016/S0378-5173(01)00602-0
Clearance characteristics of chitosan based formulations in the sheep nasal cavity.
R. Soane (2001)
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens.
H. Staats (1999)
10.1016/J.EJPB.2004.10.006
Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.
U. Bilati (2005)
10.1016/0264-410X(92)90325-E
Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens.
R. Glueck (1992)
10.1016/0264-410X(92)90439-Q
Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid.
G. Reid (1992)
10.1016/S0896-8446(01)00064-X
Particle design using supercritical fluids: Literature and patent survey
Jennifer Jung (2001)
10.1016/S0168-1656(00)00313-8
Vaccine delivery: lipid-based delivery systems.
M. Baca-Estrada (2000)
10.1016/S0168-3659(97)00036-9
Current options for vaccine delivery systems by mucosal routes
J. Mestecky (1997)
10.4049/jimmunol.170.1.495
HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses1
G. Sakaue (2003)
10.1006/SMIM.1999.0172
M cells at locations outside the gut.
A. Gebert (1999)
10.1128/IAI.67.5.2643-2648.1999
Single-Dose Mucosal Immunization with Biodegradable Microparticles Containing a Schistosoma mansoniAntigen
B. Baras (1999)
10.1016/J.ADDR.2006.01.002
Mucosal delivery of vaccine antigens and its advantages in pediatrics.
M. T. D. Magistris (2006)
10.1016/S0167-5699(99)01468-1
Regional specialization in the mucosal immune system: primed cells do not always home along the same track.
P. Brandtzaeg (1999)
10.1038/nbt1332
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
S. T. Reddy (2007)
10.1016/J.JCONREL.2004.12.020
Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy.
I. Schoell (2005)
10.1016/J.VACCINE.2005.01.139
Scale up of proteoliposome derived Cochleate production.
C. Zayas (2006)
10.1016/S0378-5173(98)00367-6
Evaluation of the clearance characteristics of bioadhesive systems in humans.
R. Soane (1999)
10.1007/0-306-46817-4_9
Cochleates. Lipid-based vehicles for gene delivery-concept, achievements and future development.
L. Zarif (2000)
10.1016/J.IT.2006.10.005
Targeting dendritic cells with biomaterials: developing the next generation of vaccines.
S. T. Reddy (2006)
10.1023/A:1013334916162
In Situ Study of Insulin Aggregation Induced by Water-Organic Solvent Interface
Y. M. Kwon (2004)
10.1038/375151A0
The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing
W. Jiang (1995)
10.1128/IAI.61.6.2390-2395.1993
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
N. Orr (1993)
10.1016/0378-5173(92)90332-V
Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid
H. O. Alpar (1992)
10.1016/J.JCONREL.2006.03.017
PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
N. Csaba (2006)
10.1016/0168-3659(90)90072-2
Microspheres of hyaluronic acid esters—Fabrication methods and in vitro hydrocortisone release
L. Benedetti (1990)
10.1016/J.VACCINE.2005.01.127
Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine.
O. Pérez (2006)
10.1080/10611860410001670017
Immunological Aspects of Polymer Microsphere Vaccine Delivery Systems
J. Eyles (2003)
10.1016/S0264-410X(97)00248-X
Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin.
M. Higaki (1998)
10.1016/0147-9571(93)E0012-5
Systemic and mucosal intestinal antibody response of sheep immunized with aromatic-dependent live or killed Salmonella typhimurium.
T. Mukkur (1995)
10.1016/J.EJPS.2006.12.006
An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells.
A. des Rieux (2007)
10.1016/J.VACCINE.2005.06.031
Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
M. Manocha (2005)
10.1128/IAI.69.7.4545-4553.2001
Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults
L. Fries (2001)
10.1007/978-1-4615-1823-5_16
Polymer microspheres for vaccine delivery.
Justin S Hanes (1995)
10.1016/S0169-409X(01)00166-1
Intranasal vaccination against plague, tetanus and diphtheria.
H. O. Alpar (2001)
In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
J. Mcghee (1990)
10.1038/308457A0
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
B. Morein (1984)
10.1046/j.1365-2249.1998.00650.x
The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
Hu (1998)
10.1016/J.VACCINE.2004.12.006
Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
L. Bracci (2005)
10.1016/0169-409X(95)00097-Q
Delivery systems for non-parenteral vaccines
A. L. W. Po (1995)
10.1016/0304-4157(95)00002-9
Liposomes and ISCOMS as vaccine formulations.
G. Kersten (1995)



This paper is referenced by
10.1021/ACSMACROLETT.7B00049
Polymer–Protein Core–Shell Nanoparticles for Enhanced Antigen Immunogenicity
X. Zhang (2017)
10.1016/j.vaccine.2010.11.010
PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration.
Armando Stano (2011)
10.1586/erv.10.89
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses
M. Oyewumi (2010)
10.4161/hv.6.7.11413
Development of improved vaccines against whooping cough: Current status
Ibrahim Marzouqi (2010)
10.1080/17425247.2020.1713746
Development of nano-carriers for Leishmania vaccine delivery
Anis Askarizadeh (2020)
10.3109/1061186X.2010.523790
Nasal vaccine innovation
I. Jabbal‐Gill (2010)
PSAA encapsulated mucoadhesive polycaprolactone microparticles as potential intranasal vaccine delivery system against pneumococcal infections / by Yamini Gorantla
Yamini Gorantla (2017)
10.1016/J.SCIENT.2013.05.012
Nanocarriers, nanovaccines, and nanobacteria as nanobiotechnological concerns in modern vaccines
P. Gill (2013)
The Way to Spray: Modeling Nasal Spray Deposition
A. Mahtani (2009)
10.5772/63453
Nanotechnologies Applied in Biomedical Vaccines
Yuan-Chuan Chen (2017)
10.3109/10837450.2012.705295
Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation
Janice M. Davis (2013)
10.3390/pharmaceutics6030378
Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives
Yingying Xu (2014)
10.1016/j.ijpharm.2019.118592
Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination.
Genada Sinani (2019)
10.1002/jps.24161
Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
Ganesh A Barhate (2014)
Transmucosal nasal drug delivery : pharmacokinetics and pharmacodynamics of nasally applied esketamine
Christoph Bitter (2011)
Live Metabolite-Deficient Bordetella pertussis: Determination of Suitability for use as a Vaccine in Humans using the Pertussis Mouse Model
I. Alhashmi (2012)
10.4155/TDE.11.80
Delivery of antigens used for vaccination: recent advances and challenges.
R. Scherließ (2011)
10.1016/j.vaccine.2012.08.050
Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems.
L. Figueiredo (2012)
Synthetic nanoparticle-based vaccines against respiratory pathogens
Kathleen A. Ross (2013)
10.1002/9781118833322.CH24
Vaccine Delivery: Current Routes of Administration and Novel Approaches
N. Sahni (2016)
10.1016/j.vaccine.2013.07.081
In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations.
R. Scherließ (2013)
10.18433/J3NC79
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
Section II: Topical Treatment of Impaired Mucosal Membranes
Christoph Bittera (2011)
10.1016/j.vaccine.2014.08.089
The mucosal immune system for vaccine development.
Aayam Lamichhane (2014)
10.1016/J.EUPROT.2014.05.003
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
T. Uhlig (2014)
10.1016/j.vaccine.2015.07.022
Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences.
R. Pabst (2015)
10.1016/j.ijpharm.2015.08.059
Design of lipid microparticle dispersions based on the physicochemical properties of the lipid and aqueous phase.
A. Lauterbach (2015)
10.1016/j.biomaterials.2016.08.035
Biomineralized vaccine nanohybrid for needle-free intranasal immunization.
X. Wang (2016)
10.1007/978-1-4614-9524-6_14
Pheroid™ Vesicles and Microsponges for Nasal Delivery of Biopharmaceuticals
L. D. Plessis (2014)
10.1007/978-3-642-36853-0
DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases
V. Erdmann (2013)
10.1201/B13159-2
Nanomedicine: Emerging Field of Nanotechnology to Human Health
Chandana Mohanty (2012)
10.3389/fmicb.2015.01012
Present and future medical applications of microbial exopolysaccharides
M. Moscovici (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar